Font Size:

Healthcare Providers


Please complete the Monkeypox Testing Consultation Form for Healthcare Providers to report any suspected cases of monkeypox.

Download Guidance for Monkeypox Specimen Collection and Shipping

At this time, testing for monkeypox can only be performed at public health laboratories and some commercial laboratories. The Alabama Department of Public Health is available to assist with monkeypox evaluation and testing. If testing is warranted after we review the information provided in this survey, you will be contacted by ADPH staff for the next steps.

Table of Contents

What's New?

COCA Call - CDC and FDA Update: Interim Clinical Considerations for Monkeypox Vaccination (August 11, 2022)

COCA Call - Monkeypox: Updates on the Epidemiology, Testing, Treatment, and Vaccination (July 26, 2022)

CDC/IDSA Call - Monkeypox: Updates on Testing, Vaccination and Treatment (July 23, 2022)

COCA Call - Monkeypox: Updates about Clinical Diagnosis and Treatment (June 29, 2022)

Monkeypox Virus Planning Response (Video)

Dr. Walensky's Dear Colleagues Letter for Clinicians

WHO Meeting of the International Health Regulations Emergency Committee


HAN Alerts

08/02/22 - Monkeypox Situation Update

07/18/22 - Testing for Monkeypox (MPX) in Jefferson County

07/08/22 - Guidance for Monkeypox Test Submission

06/18/22 - CDC and ADPH Health Advisory on Monkeypox Virus Infections in the United States and Other Non-endemic Countries – 2022

05/26/22 - UPDATED with additional Epidemiologic, Clinical, and Exclusion Criteria: CDC and ADPH Health Advisory on Monkeypox Virus Infections in the United States and Other Non-endemic Countries - 2022

05/23/22 - CDC and ADPH Health Advisory on Monkeypox Virus Infections in the United States and Other Non-endemic Countries - 2022

Visit the Health Alert Network (HAN) for CDC's HAN Messages.

Additional Resources

ACIP Meeting Presentations

More presentations are available at ACIP Meetings.

Children and Adolescents

Monkeypox should be considered when children or adolescents present with a rash that could be consistent with the disease, especially if epidemiologic criteria are present. Young children, children with eczema and other skin conditions, and children with immunocompromising conditions may be at increased risk of severe disease. Treatment should be considered on a case-by-case basis for children and adolescents with suspected or confirmed monkeypox who are at risk of severe disease or who develop complications of monkeypox. Tecovirimat is the first-line medication to treat monkeypox, including in children and adolescents. Children and adolescents with exposure to people with suspected or confirmed monkeypox may be eligible for post-exposure prophylaxis (PEP) with vaccination, immune globulin, or antiviral medication. For more information, read:

Pregnancy and Breastfeeding

Data regarding monkeypox infection in pregnancy are limited. It is unknown if pregnant people are more susceptible to the Monkeypox virus or if the infection is more severe during pregnancy. Monkeypox virus can be transmitted to the fetus during pregnancy or to the newborn by close contact during and after birth. Adverse pregnancy outcomes, including spontaneous pregnancy loss and stillbirth, have been reported in cases of confirmed monkeypox infection during pregnancy. Preterm delivery and neonatal monkeypox infection have also been reported. The frequency and risk factors for severity and adverse pregnancy outcomes are not known. For more information, read:


There are no treatments specifically for monkeypox virus infections. However, monkeypox and smallpox viruses are genetically similar, which means that antiviral drugs and vaccines developed to protect against smallpox may be used to prevent and treat monkeypox virus infections.

Antivirals, such as tecovirimat (TPOXX), may be recommended for people who are more likely to get severely ill, like patients with weakened immune systems. For information concerning monkeypox therapeutics and obtaining TPOXX, read:


Two vaccines may be used for the prevention of Monkeypox virus infection:

  • JYNNEOS (also known as Imvamune or Imvanex), licensed (or approved) by the U.S. Food and Drug Administration (FDA) for the prevention of Monkeypox virus infection, and ACAM2000, licensed (or approved) by FDA for use against smallpox and made available for use against monkeypox under an Expanded Access Investigational New Drug application.
  • In the United States, there is currently a limited supply of JYNNEOS, although more is expected in the coming weeks and months.
  • There is a larger supply of ACAM2000, but this vaccine should not be used in people who have certain health conditions, such as a weakened immune system, skin conditions like eczema or other exfoliative skin conditions, or pregnancy.
  • No data are available yet on the effectiveness of these vaccines in the current outbreak.
  • The immune response takes 14 days after the second dose of JYNNEOS and 4 weeks after the ACAM2000 dose for maximal development.
  • People who get vaccinated should continue to take steps to protect themselves from infection by avoiding close, skin-to-skin contact, including intimate contact, with someone who has monkeypox.
  • To better understand the protective benefits of these vaccines in the current outbreak, CDC will collect data about adverse events and vaccine effectiveness, including whether the vaccine protects a person differently depending on how they were infected with the Monkeypox virus.

For more information, read Considerations for Monkeypox Vaccination.

Page last updated: August 15, 2022